Roche Breaks Into Bladder Cancer, But Merck Is Hot On Its Heels
Roche leads the way in bladder cancer, with a strong response rate in a Phase Ib study and “breakthrough therapy” status. But Merck says that it has “very good” undisclosed data in-house and plans to kick off a full registration program soon.
You may also be interested in...
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.
Patients with the most severe type of disease were all randomized to treatment with the study drug, which may have had a negative impact on outcome, the Israeli company suggested.